vision loss
Novartis’ gene therapy Luxturna becomes first approved European therapy for vision loss subtype
November 23, 2018Medical Communications, Sales and Marketing EU, Europe, Luxturna, Novartis, pharma, vision loss
Novartis has revealed that its one-time gene therapy Luxturna (voretigene neparvovec) has been awarded approval by the European Commission to …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
